Literature DB >> 10592229

Kabat database and its applications: 30 years after the first variability plot.

G Johnson1, T T Wu.   

Abstract

The Kabat Database was initially started in 1970 to determine the combining site of antibodies based on the available amino acid sequences at that time. Bence Jones proteins, mostly from human, were aligned, using the now-known Kabat numbering system, and a quantitative measure, variability, was calculated for every position. Three peaks, at positions 24-34, 50-56 and 89-97, were identified and proposed to form the complementarity determining regions (CDR) of light chains. Subsequently, antibody heavy chain amino acid sequences were also aligned using a different numbering system, since the locations of their CDRs (31-35B, 50-65 and 95-102) are different from those of the light chains. CDRL1 starts right after the first invariant Cys 23 of light chains, while CDRH1 is eight amino acid residues away from the first invariant Cys 22 of heavy chains. During the past 30 years, the Kabat database has grown to include nucleotide sequences, sequences of T cell receptors for antigens (TCR), major histocompatibility complex (MHC) class I and II molecules and other proteins of immunological interest. It has been used extensively by immunologists to derive useful structural and functional information from the primary sequences of these proteins. An overall view of the Kabat Database and its various applications are summarized here. The Kabat Database is freely available at http://immuno.bme.nwu.edu

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10592229      PMCID: PMC102431          DOI: 10.1093/nar/28.1.214

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  14 in total

1.  Random length assortment of human and mouse T cell receptor for antigen alpha and beta chain CDR3.

Authors:  G Johnson; T T Wu
Journal:  Immunol Cell Biol       Date:  1999-10       Impact factor: 5.126

2.  Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites.

Authors:  E A Kabat; T T Wu
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

3.  An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex.

Authors:  K C Garcia; M Degano; R L Stanfield; A Brunmark; M R Jackson; P A Peterson; L Teyton; I A Wilson
Journal:  Science       Date:  1996-10-11       Impact factor: 47.728

4.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution.

Authors:  A G Amit; R A Mariuzza; S E Phillips; R J Poljak
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

5.  Generation of the primary antibody repertoire in rabbits: expression of a diverse set of Igk-V genes may compensate for limited combinatorial diversity at the heavy chain locus.

Authors:  D Sehgal; G Johnson; T T Wu; R G Mage
Journal:  Immunogenetics       Date:  1999-10       Impact factor: 2.846

6.  Structure of the complex between human T-cell receptor, viral peptide and HLA-A2.

Authors:  D N Garboczi; P Ghosh; U Utz; Q R Fan; W E Biddison; D C Wiley
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

7.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

8.  A method of estimating the numbers of human and mouse immunoglobulin V-genes.

Authors:  G Johnson; T T Wu
Journal:  Genetics       Date:  1997-03       Impact factor: 4.562

9.  Preferred CDRH3 lengths for antibodies with defined specificities.

Authors:  G Johnson; T T Wu
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

10.  An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity.

Authors:  T T Wu; E A Kabat
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

View more
  41 in total

1.  Kabat Database and its applications: future directions.

Authors:  G Johnson; T T Wu
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Role of native-state topology in the stabilization of intracellular antibodies.

Authors:  G Settanni; A Cattaneo; A Maritan
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

3.  Diversification of the Ig variable region gene repertoire of synovial B lymphocytes by nucleotide insertion and deletion.

Authors:  Yasushi Miura; Charles C Chu; David M Dines; Stanley E Asnis; Richard A Furie; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2003 May-Aug       Impact factor: 6.354

4.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.

Authors:  Fabio Ghiotto; Franco Fais; Angelo Valetto; Emilia Albesiano; Shiori Hashimoto; Mariella Dono; Hideyuki Ikematsu; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Marco Nardini; Anna Tramontano; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

5.  Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies.

Authors:  Brett A Thibodeaux; Amanda N Panella; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

6.  Two-state selection of conformation-specific antibodies.

Authors:  Junjun Gao; Sachdev S Sidhu; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

Review 7.  Developments in therapy with monoclonal antibodies and related proteins.

Authors:  H Michael Shepard; Gail Lewis Phillips; Christopher D Thanos; Marc Feldmann
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

8.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

9.  Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies.

Authors:  Brett A Thibodeaux; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2009-03-18

10.  Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.

Authors:  Tongqing Zhou; I-Ting Teng; Adam S Olia; Gabriele Cerutti; Jason Gorman; Alexandra Nazzari; Wei Shi; Yaroslav Tsybovsky; Lingshu Wang; Shuishu Wang; Baoshan Zhang; Yi Zhang; Phinikoula S Katsamba; Yuliya Petrova; Bailey B Banach; Ahmed S Fahad; Lihong Liu; Sheila N Lopez Acevedo; Bharat Madan; Matheus Olivera de Souza; Xiaoli Pan; Pengfei Wang; Jacy R Wolfe; Michael Yin; David D Ho; Emily Phung; Anthony DiPiazza; Lauren Chang; Olubukula Abiona; Kizzmekia S Corbett; Brandon J DeKosky; Barney S Graham; John R Mascola; John Misasi; Tracy Ruckwardt; Nancy J Sullivan; Lawrence Shapiro; Peter D Kwong
Journal:  SSRN       Date:  2020-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.